Biotheus Expanded Partnership with Hansoh Pharma for Developing EGFR/cMET Bispecific ADCs
“This is the second collaboration between Hansoh and Biotheus. We really appreciate Hansoh’s confidence in the potential of PM1080”, said Mr. Xiaolin Liu, Co-founder, Chairman and Chief Executive Officer of Biotheus. “Bispecific ADCs have a potential advantage for better tumor enrichment, overall efficacy and safety. Hansoh develops an outstanding ADC platform, and this collaboration will facilitate the synergy between Hansoh’s ADC expertise and Biotheus’ antibody capabilities. Through this collaboration, we hope to develop a novel EGFR/cMet bispecific ADC with better efficacy and safety for cancer patients worldwide.”
Share:
More News
“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”
“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two
Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius, said: “The positive CHMP opinion for the sqNSCLC indication marks another important milestone in serplulimab’s regulatory journey in Europe and brings the product one step closer to achieving comprehensive coverage of first-line lung cancer treatment indications in the EU.